Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia

Published:2018-04-03 Issue:2 Volume:31 Page:180-184
ISSN:0899-8280
Container-title:Baylor University Medical Center Proceedings
language:en
Short-container-title:Baylor University Medical Center Proceedings

Author:

Zhang Jun¹,Tecson Kristen M.¹,Rocha Natalia A.²,McCullough Peter A.¹³

Affiliation:

1. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas

2. Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas

3. Division of Cardiology, Baylor Jack and Jane Hamilton Hospital, Dallas, Texas

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/08998280.2018.1441255

Reference24 articles.

1. Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes

2. Pharmacological management of diabetic dyslipidemia

3. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II

4. Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

5. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug development advances in human genetics‐based targets;MedComm;2024-02

2. PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells;International Journal of Molecular Sciences;2023-03-07

3. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging;Theranostics;2023

4. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022);Cardiovascular Diabetology;2022-11-28

5. Critical Role of LOX-1-PCSK9 Axis in the Pathogenesis of Atheroma Formation and Its Instability;Heart, Lung and Circulation;2021-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3